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Summary
Objectives: To evaluate the role of non-traditional biochemical markers, and carotid
and femoral Doppler in early detection of atherosclerosis in asymptomatic cardio-
vascular risk patients.
Subjects and methods: This study was conducted on 72 patients with various car-
diovascular risk factors (22 diabetic, 15 hypertensive, 20 smokers, and 15 obese),
in addition to 18 healthy controls. All of them were subjected to complete exam-
ination, anthropometric measurements, calculation of Framingham risk score (FS)
and measurement of lipoprotein (a) (Lp(a)), homocysteine, insulin, C-reactive pro-
tein (CRP) and microalbumin in urine (UAER) and calculation of insulin sensitivity.
Intima—media thickness (IMT) and plaque formation were assessed in both carotid
and femoral arteries.
Results: Mean values of serum insulin, homocysteine, CRP, UAER, and the IMT of right
and left common carotid, and right femoral arteries revealed signiﬁcant elevation
in all studied groups compared to controls and insulin sensitivity showed signiﬁcant
reduction. In group C (FS≥ 20%) the mean values of triglycerides, Lp(a), and IMT of
right femoral, right carotid, and left carotid arteries showed signiﬁcant elevation
compared to group A (FS < 10%) (p < 0.01). Age, waist circumference, waist/hip ratio,
homocysteine, triglycerides, and CRP were predictors of IMT of carotid artery, while
age, CRP, and triglycerides were predictors of atheroma.
∗ Corresponding author. Tel.: +20 105766155; fax: +20 882333327.
E-mail address: salwaelgendi@yahoo.com (S.S. El-Gendi).
0914-5087/$ — see front matter © 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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Conclusion: Non-traditional biochemical markers were elevated in all studied cardio-
vascular risk groups. IMT of carotid artery correlated with traditional risk factors and
FS, as well as non-traditional risk factors. Carotid IMT measurement is recommended
in both primary and secondary coronary heart disease prevention.
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This study involved 72 patients with various cardio-
vascular risk factors in Assiut University Hospitals.© 2008 Japanese Colleg
reserved.
ntroduction
therosclerosis is a major cause of death and it is
ssociated with cardiovascular and cerebrovascu-
ar diseases. Some risk factors for atherosclerosis
re currently well known, such as age, sex, dys-
ipidemia, smoking, obesity, and genetic factors
1]. Despite the availability of effective preven-
ive therapies, coronary artery disease remains the
ain cause of death. Use of traditional cardiovas-
ular risk factors is imprecise and predicts less than
ne half of future cardiovascular events [2].
Efforts have focused on non-invasive imaging of
therosclerosis in coronary tree or other arterial
urrogates, and novel serum markers that may
redict future events. Atherosclerotic changes in
arotid and femoral arteries are easy to be observed
y a non-invasive high-resolution ultrasonic
achine that is reliable for diagnosis of preclinical
therosclerosis [3]. There was a positive association
etween intima—media thickness (IMT) of arterial
all and traditional risk factors such as hyperten-
ion, dyslipidemia, diabetes mellitus, and cigarette
moking [4]. Carotid IMT has been recognized
ecently as a surrogate marker to evaluate thera-
eutic interventions in atherosclerotic disease [5].
Traditional risk factors are thought to induce
nﬂammatory reaction and to cause the devel-
pment of atherosclerosis [6]. C-reactive protein
CRP) is a member of the pentraxin family, which
onsists of ﬁve non-covalently associated peptides
urrounding a central core, binding bacterial and
ungal polysaccharides [7]. Mild elevations in CRP
redict myocardial infarction, stroke, and vascular
eath in a variety of clinical settings [8].
Insulin resistance has been observed with
ssential hypertension, in non-insulin-dependent
iabetes with hypertriglyceridemia and in smoking,
ll are risk factors for atherosclerosis [9]. Insulin
esistance is associated with arterial wall stiffness,
nd is thought to contribute to the initiation of early
tages of atherosclerosis [10].
Homocysteine (tHcy) is a sulfur-containing amino
cid formed during metabolism of methionine
11]. Elevated levels of tHcy are toxic to vascu-
ar endothelium, causing endothelial dysfunction
nd contributing to development of atherosclero-
is independent of cardiovascular risk factors in
T
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w
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iabetics or non-diabetics [12]. Also elevated tHcy
evel was associated with atherogenic and throm-
ogenic tendencies [11].
Lipoprotein (a) (Lp(a)) has many properties in
ommon with low-density lipoprotein cholesterol
LDL-c). Lp(a) contains a unique protein apolipopro-
ein (a) (Apo (a)), which is structurally different
rom other apolipoproteins. Apo (a) is linked to Apo
through a single disulﬁde bond connecting their C
erminal regions. Lp(a) has a high degree of homol-
gy with plasminogen [13].
Although the concentration of Lp(a) is mostly
enetically determined, acquired disorders might
nﬂuence synthesis and catabolism of the particle.
aised levels of Lp(a) have been acknowledged as
n inherited risk for both premature and advanced
therosclerosis at different vascular sites [14].
p(a) is an important risk factor for cardiovascular
isease, and is associated with ischemic heart dis-
ase, age, dyslipidemia, body fat, and Framingham
core [15].
Microalbuminuria (20—200g/min) may repre-
ent more generalized vascular damage than renal
icrovascular injury alone. There is an associa-
ion between urinary albumin excretion rate (UAER)
ith diabetes, hypertension, dyslipidemia, hyper-
omocysteinemia, and smoking [16].
im of the work
1) To study the role of non-traditional serum mark-
ers including Lp(a), tHcy, insulin, and CRP as
well as microalbuminuria in the atherosclerotic
process.
2) To elucidate whether these serum markers have
an additional inﬂuence on carotid and femoral
IMT.
ubjects and methodsheir mean age was 50.8± 6.5 S.D. years. Twenty-
wo patients had type II diabetes mellitus. They
ere diagnosed according to the American Diabetes
ssociation guidelines [17]. Fifteen were hyperten-
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sive. Hypertension was diagnosed if the patient had
a history of hypertension and was taking antihy-
pertensive drugs or had a resting recumbent blood
pressure >140/90mmHg on at least two occasions
[18]. Also, 15 overweight and obese patients were
included (BMI > 25 kg/m2), and 20 cigarette smok-
ers. Each patient had only one CV risk factor.
Also, 18 age- and sex-matched subjects were
enrolled as a control group. All subjects gave oral or
written informed consent to take part in the study,
which was approved by the ethics committee of our
institution. We excluded patients with cardiovascu-
lar, cerebrovascular, or peripheral vascular disease.
All patients and controls were subjected to
complete history, clinical examination, and anthro-
pometric measurements, BMI (weight (kg)/height
(m2)), waist and hip circumferences, and waist
to hip ratio (w/h), and ECG were done for all
subjects.
Fasting blood specimen was taken and serum was
separated, aliquoted, and stored frozen at −70 ◦C
until analysis.
The following laboratory investigations were
done for all subjects:
• Serum glucose, kidney, liver function tests, and
lipogram were all done on Hitachi 911 (Roche
Diagnostics GmbH, Mannheim, Germany).
• Fasting serum insulin level was performed on
Immulite automated analyzer using immuno-
metric assay (Catalog Number LKIN1, kit from
Diagnostic Products Corporation (DPC), Los Ange-
les, USA).
• Calculation of insulin sensitivity: Quantita-
tive insulin sensitivity check index (QUICKI) =
1/log(fasting serum insulin) + log(fasting serum
glucose) [19].
• Lp(a) was performed using an enzyme immunoas-
say (ELISA), ELITEST, Lp(a) Catalog Number,
CK103A, kit from HYPHEN BioMed (France).
• CRP was assessed using latex agglutination test,
kit from Omega Diagnostics Ltd. (Scotland, UK).
• Microalbumin (in urine) was assessed using a com-
petitive solid phase enzyme immunoassay, with
calculation of UAER (g/min), kit supplied by
ORGENTEC Diagnostika GmbH (Mainz, Germany).
• Framingham cardiovascular risk score calculation
(FS) according to Wilson et al. [20]. The risk
factors included in the Framingham calculation
of 10-year cardiovascular risk are age, LDL-c,
high-density lipoprotein cholesterol (HDL-c), sys-
tolic blood pressure, diastolic blood pressure,
diabetes, and cigarette smoking.
• Doppler of the femoral and carotid arter-
ies were done for all subjects using a
computed color duplex system Acuson 128
r
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XP/10 (Duluth, USA) to provide an index of
atherosclerosis with Linear 7MHz transducer
(Duluth, USA). Measurement of IMT of carotid
and femoral arteries was performed, in addition
to evaluation of the presence of plaques (deﬁned
as a localized thickening of >1.2mm not involv-
ing the whole circumference of the artery). IMT
measurements were performed at six sites, both
common carotid arteries, the bulb, and internal
carotid arteries.
tatistical analysis
ll data are represented as means± S.D. Compari-
on between groups was done by Student’s t-test.
orrelation between variables was performed by
earson correlation coefﬁcients. Estimation of IMT
redictors was performed by linear regression anal-
sis. Predictors of atheroma and estimation of odds
atio at conﬁdence interval 95% was done by logistic
egression analysis. A p-value < 0.05 was considered
igniﬁcant. The statistical analysis was performed
n SPSS Version 11.
esults
he results of this study are illustrated in
ables 1—6. Patients were classiﬁed according to
ramingham risk score into three groups: group A,
S < 10% (40 patients); group B, FS 10≤ 20% (25
atients); and group C, FS≥ 20% (7 patients).
Also, patients were classiﬁed according to
theroma presence into two groups: group I,
atients without atheroma (62 patients) and group
I, patients with atheroma (10 patients).
Table 1 shows clinical and Doppler character-
stics of the studied patient groups. The mean
alues of IMT of right femoral, right and left carotid
rteries were increased in diabetic, hypertensive,
moker, and obese patient groups compared to con-
rols, while left femoral IMT was increased in the
ypertensive group only.
Mean values of serum cholesterol, triglycerides,
nd LDL-c revealed signiﬁcant elevation in diabetic
nd hypertensive groups compared to controls.
riglyceride level also showed signiﬁcant elevation
n both smoker and obese groups compared to con-
rols. HDL-c showed signiﬁcant reduction in smoker
roup only compared to controls (Table 2).
Mean values of insulin, CRP, tHcy, and UAER
evealed signiﬁcant elevation in all studied groups
ompared to controls. Lp(a) revealed signiﬁ-
ant elevation in smoker group in comparison to
ontrols; in other studied groups Lp(a) showed sta-
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Table 1 Clinical and Doppler characteristics of the studied groups (mean± S.D.)
Parameters Groups
Controls (n = 18) DM (n = 22) HT (n = 15) Obese (n = 15) Smoker (n = 20)
Age (years) 46.11 ± 5.71 52.95 ± 6.48 53.35 ± 6.96 47.25 ± 4.27 49.33 ± 6.13
BMI (kg/m2) 21.91 ± 2.18 28.94 ± 4.10** 29.81 ± 5.56** 33.54 ± 8.80** 27.0 ± 10.82*
Waist circumference (cm) 84.56 ± 7.47 103.55 ± 11.45** 101.06 ± 11.97** 111.06 ± 17.39** 92.38 ± 16.51
Waist/hip ratio 0.91 ± 0.08 0.97 ± 0.06** 0.96 ± 0.08** 0.99 ± 0.06** 0.95 ± 0.09**
SBP (mmHg) 120.00 ± 10.85 120.45 ± 11.33 135.29 ± 18.41* 123.13 ± 13.02 119.5 ± 8.65
DBP (mmHg) 74.44 ± 7.05 75.00 ± 7.40 85.29 ± 15.46* 78.13 ± 7.50 77.14 ± 7.84
Right femoral IMT (mm) 0.73 ± 0.14 0.90 ± 0.28* 0.98 ± 0.26** 0.91 ± 0.20** 0.90 ± 0.23**
Left femoral IMT (mm) 0.79 ± 0.20 0.88 ± 0.18 0.99 ± 0.38* 0.84 ± 0.20 0.86 ± 0.26
Right CCA IMT (mm) 0.60 ± 0.08 0.79 ± 0.20* 0.86 ± 0.17* 0.75 ± 0.15* 0.8 ± 0.19*
Left CCA IMT (mm) 0.60 ± 0.11 0.85 ± 0.19** 0.87 ± 0.15** 0.73 ± 0.13** 0.85 ± 0.14**
*p < 0.05; **p < 0.01. DM, diabetes mellitus; HT, hypertension; CCA, common carotid artery; IMT, intima—media thickness.
Table 2 Laboratory characteristics of the studied groups (mean± S.D.)
Tests Groups
Controls (n = 18) DM (n = 22) HT (n = 15) Obese (n = 15) Smoker (n = 20)
Fasting serum glucose (mmol/l) 4.73 ± 0.61 9.10 ± 3.87** 5.05 ± 0.93 4.86 ± 0.62 4.46 ± 0.33
After 2 h serum glucose (mmol/l) 5.57 ± 0.71 11.89 ± 5.45** 6.13 ± 1.72 6.06 ± 1.76 5.47 ± 0.67
Fasting insulin level (lu/ml) 4.60 ± 2.76 11.56 ± 4.57** 7.61 ± 3.54** 10.04 ± 4.99** 13.71 ± 1.44**
Insulin sensitivity 0.82 ± 0.21 0.66 ± 0.15** 0.41 ± 0.17** 0.45 ± 0.23** 0.46 ± 0.14**
Cholesterol (mg/dl) 162.67 ± 28.32 196.91 ± 40.40** 205.94 ± 37.80* 195.31 ± 37.90** 180.33 ± 37.94
LDL-c (mg/dl) 95.33 ± 29.63 122.23 ± 39.50* 124.65 ± 31.17* 118.31 ± 26.95 111.24 ± 35.44
HDL-c (mg/dl) 50.78 ± 16.76 42.09 ± 17.16 47.18 ± 15.08 47.19 ± 10.70 39.52 ± 8.96**
Triglycerides (mg/dl) 81.78 ± 20.02 165.09 ± 87.12** 165.71 ± 85.37** 149.13 ± 67.89* 138.67 ± 34.85*
Lp(a) (mg/dl) 9.73 ± 6.07 14.81 ± 14.11 9.96 ± 7.33 13.84 ± 9.79 20.83 ± 27.69**
CRP (mg/l) 6.67 ± 0.94 14.63 ± 12.69** 24.31 ± 28.02** 40.40 ± 39.65** 14.67 ± 13.04*
Homocysteine (mol/l) 7.19 ± 1.64 13.41 ± 5.17** 14.72 ± 1.95** 10.94 ± 1.95** 17.33 ± 4.67**
UAER (g/min) 11.27 ± 6.01 229.15 ± 268.38** 118.34 ± 164.81** 257.52 ± 295.57** 161.36 ± 181.38**
*p < 0.05; **p < 0.01. DM, diabetes mellitus; HT, hypertension; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; Lp(a), lipoprotein (a); CRP,
C-reactive protein; UAER, urinary albumin excretion rate.
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tistically insigniﬁcant elevation. Insulin sensitivity
(QUICKI) revealed signiﬁcant reduction in the stud-
ied groups compared to controls (Table 2).
In the smoker group, the mean value of Lp(a)
showed signiﬁcant elevation compared to the
hypertensive group (p < 0.05). Also, CRP in the
obese group revealed signiﬁcant elevation com-
pared to the diabetic group; other parameters
revealed no signiﬁcant differences when comparing
the studied groups versus each other.
In group C (FS≥ 20%), the mean values of triglyc-
erides, Lp(a), and IMT of right femoral, right
carotid, and left carotid arteries showed signiﬁcant
elevation compared to group A (FS < 10%) (p < 0.01,
0.01, 0.01, 0.05, and 0.001, respectively) (Table 3).
In atheroma group (II),the mean value of SBP, DBP,
insulin, CRP, and triglycerides showed signiﬁcant
elevation compared to group (I) non atheroma
patients (p < 0.05, 0.001, 0.05, 0.05, and 0.05,
respectively), while insulin sensitivity revealed sig-
niﬁcant reduction (p < 0.05) (Table 4).
By multiple linear regression analysis taking
age, BMI, waist/hip ratio, waist circumference,
systolic blood pressure, diastolic blood pressure,
lipid, Lp(a), insulin, tHcy, and UAER as independent
risk predictors for IMT of carotid artery (depen-
dent variable), we found that age, triglycerides,
CRP, tHcy, waist/hip ratio, and waist circumfer-
ence were independent factors associated with
intima—media thickness of carotid artery (Table 5).
Using logistic regression analysis for predictors of
atheroma all the studied parameters are indepen-
dent risk factors. The most signiﬁcant factors for
atheroma prediction were CRP (p = 0.04, OR 5.6),
Table 3 Parameters studied in patients classiﬁed accordin
Tests Group
A (FS < 10%)
No = 40
B (FS 10≤ 20
No = 25
BMI (kg/m2) 29.3 ± 7.2 30.4 ± 5.7
Waist circumference (cm) 99.8 ± 17.3 104.5 ± 13.
Waist/hip 0.9 ± 0.08 0.9 ± 0.0
S. triglycerides (mg/dl) 136.4 ± 57.1 164.0 ± 68.
Lp(a) (mg/dl) 14.3 ± 16.3 11.1 ± 8.0
Insulin (lu/ml) 7.9 ± 4.5 8.5 ± 5.8
Insulin sensitivity 0.69 ± 0.17 0.67 ± 0.1
CRP (mg/l) 25.5 ± 30.1 16.9 ± 13.
Homocysteine (mol/l) 14.0 ± 5.1 14.6 ± 4.2
UAER (g/min) 193.1 ± 240.7 188.7 ± 244
Right femoral IMT (mm) 0.8 ± 0.2 0.9 ± 0.2
Left femoral IMT (mm) 0.8 ± 0.1 0.9 ± 0.3
Right CCA IMT (mm) 0.74 ± 0.14 0.8 ± 0.1
Left CCA IMT (mm) 0.74 ± 0.16 0.85 ± 0.1
FS, Framingham risk score; BMI, body mass index; S., serum; Lp(a), l
excretion rate; IMT, intima—media thickness; CCA, common carotid
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riglycerides (p = 0.05, OR 7.3), and age (p = 0.02,
R 1.9) (Table 6).
orrelation study
ositive correlations were found between left
arotid artery IMT and BMI (r = 0.25; p < 0.01),
ystolic blood pressure (r = 0.29; p < 0.001), dias-
olic blood pressure (r = 0.25; p < 0.01), cholesterol
r = 0.26; p < 0.01), LDL-c (r = 0.19; p < 0.05), triglyc-
ride (r = 0.24; p < 0.001), CRP (r = 0.24; p < 0.01),
Hcy (r = 0.24; p < 0.01), and FS (r = 0.55; p < 0.001)
nd negative correlation with HDL (r =−0.21;
< 0.05) and insulin sensitivity (r =−0.28; p < 0.01).
ositive correlations were found between insulin
nd both triglycerides (r = 0.19; p < 0.05) and
holesterol (r = 0.18; p < 0.05).
Also, negative correlations were found between
nsulin sensitivity with BMI, cholesterol, and triglyc-
rides (r =−0.2, −0.18, −0.24; p < 0.01, <0.05,
nd <0.01, respectively). Also, Lp(a) correlated
ositively with tHcy (r = 0.35; p < 0.001) and triglyc-
rides with CRP (r = 0.19; p < 0.01).
iscussion
ardiovascular disease is multifactorial in etiology.g to Framingham risk score (mean± S.D.)
%) C (FS≥ 20%)
No = 7
A vs. B A vs. C B vs. C
26.2 ± 2.9 N.S. N.S. N.S.
2 101.1 ± 12.7 N.S. N.S. N.S.
5 0.9 ± 0.03 <0.05 N.S. N.S.
2 212.4 ± 113 N.S. <0.01 N.S.
34.2 ± 34.9 N.S. <0.01 <0.01
7.8 ± 3.2 N.S. N.S. N.S.
8 0.58 ± 0.16 N.S. N.S. N.S.
1 24.0 ± 35.6 N.S. N.S. N.S.
14.5 ± 2.5 N.S. N.S. N.S.
218 ± 194 N.S. N.S. N.S.
1 ± 0.3 N.S. <0.01 N.S.
0.8 ± 0.2 <0.01 N.S. N.S.
8 0.88 ± 0.25 N.S. <0.05 N.S.
5 0.99 ± 0.19 <0.01 <0.001 N.S.
ipoprotein (a); CRP, C-reactive protein; UAER, urinary albumin
artery.
raditional cardiovascular risk factors are used to
ssess cardiovascular disease risk [21]. tHcy and
ipoprotein (a) are emerging risk factors potentially
seful in predicting future cardiac events [2,15].
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Table 4 Characteristics of patients classiﬁed according to occurrence of atheroma (mean± S.D.)
Parameters Groups p-Value
Group I (n = 62) Group II (n = 10)
Age (years) 50.5 ± 6.2 52.3 ± 8.2 N.S.
Waist circumference (cm) 101.4 ± 15.8 103.3 ± 14/6 N.S.
Waist/hip ratio 0.96 ± 0.7 0.98 ± 0.07 N.S.
BMI (kg/m2) 29.5 ± 6.9 28.8 ± 3.7 N.S.
SBP (mmHg) 122.3 ± 18.0 134.5 ± 16.9 <0.05
DBP (mmHg) 77.6 ± 8.4 82.7 ± 16.7 <0.001
S. cholesterol (mg/dl) 191.5 ± 37.3 198.6 ± 371 N.S.
S. triglycerides (mg/dl) 149.9 ± 62.0 171.4 ± 110± 1 <0.05
LDL-c (mg/dl) 116 ± 8± 33.6 123.6 ± 29.4 N.S.
HDL-c (mg/dl) 44.2 ± 13.6 39.0 ± 13.7 N.S.
Lp(a) (mg/dl) 15.7 ± 18.3 10.9 ± 12.3 N.S.
Insulin (lu/ml) 7.7 ± 4.8 10.7 ± 4.6 <0.05
Insulin sensitivity 0.6 ± 02 0.5 ± 0.1 <0.05
CRP (mg/l) 20.2 ± 24.3 35.1 ± 33.4 <0.05
Homocysteine (mol/l) 14.2 ± 4.8 14.2 ± 2.6 N.S.
UAER (g/min) 198.6 ± 242.5 166.9 ± 193.6 N.S.
Right femoral IMT (mm) 0. 90 ± 0.25 0.86 ± 020 N.S.
Left femoral IMT (mm) 0.86 ± 0.21 1.0 ± 0.45 N.S.
Right CCA IMT (mm) 0.78 ± 0.18 0.88 ± 0.16 N.S.
Left CCA IMT (mm) 0.81 ± 0.16 0.90 ± 0.17 N.S.
Framingham risk score (%) 9.1 ± 5.9 11.9 ± 7.1 N.S.
Table 5 Predictors of IMT of carotid arteries
Variable Mean common carotid
artery
Left common carotid
artery
Left internal carotid
artery
ˇ p-Value ˇ p-Value ˇ p-Value
Age 0.46 0.000 0.40 0.000 0.35 0.000
Triglycerides 0.18 0.02 — — 0.28 0.002
Homocysteine 0.16 0.04 0.21 0.01 —
CRP — 0.25 0.002 —
Waist circumference —
Waist/hip ratio —
Recently better understanding of the inﬂammation
role in atherosclerosis has prompted many to pro-
pose measurement of various inﬂammatory markers
to better identify those who are at increased risk
[21].
In addition to clinical and biochemical risk
factors, carotid IMT testing is recognized as a
valid method for the non-invasive assessment of
atherosclerosis [22].
Table 6 Predictors of atheroma
Variables p-Value Odd ratio (CI)
CRP 0.04 5.6 (1.06—30.7)
Triglycerides 0.05 7.3 (0.9—29.8)
Age 0.02 1.9 (1.2—3.3)
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— 0.22 0.03
In this study, measurement of traditional risk fac-
ors and novel non-traditional cardiovascular risk
actors, carotid and femoral artery Dopplers were
tudied in asymptomatic cardiovascular risk groups
or early detection of future cardiac events.
The mean values of serum insulin revealed sig-
iﬁcant elevation in hypertensive, diabetic, obese,
nd smoker groups compared to controls, while
nsulin sensitivity revealed signiﬁcant reductions. In
his work, there were positive correlations between
nsulin with cholesterol and triglycerides and neg-
tive correlations between insulin sensitivity and
MI, cholesterol, triglycerides, and IMT of carotid
rtery.
Insulin resistance and hyperinsulinemia are
hought to contribute to initiation of early stage of
therosclerosis. Alteration of glucose metabolism
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and insulin action substantially alter the structure
and function of arterial wall and stimulate the
proliferation of arterial smooth muscle cells, with
initiation and progression of atherosclerosis [23].
Dysregulation of insulin contributes to sys-
temic inﬂammation [24]. Insulin resistance causes
endothelial dysfunction, vascular injury, and
atherosclerosis. Insulin resistance and inﬂamma-
tion contribute to atherosclerosis by oxidative
stress throughout the body. Oxidized cholesterol
is deposited in the endothelium and begins the
process of vascular damage. Insulin resistance
is closely associated with low HDL-c. In dia-
betics, the production of advanced glycation
end products ampliﬁes the process of vascular
injury [23].
The effect of insulin resistance on IMT and
plaque formation are mediated through other risk
factors such as age, blood pressure, and lipid dis-
turbances [9]; this may be mediated by increased
portal free fatty acids, by hepatic or muscle fat, or
by decreased adiponectin [7]. On the other hand,
insulin resistance may be associated with arterial
stiffness, independent of age, blood pressure, gen-
der, or heart rate [10].
In this study, UAER mean values showed signif-
icant elevation in diabetic, hypertensive, obese,
and smoker groups compared to control group and
no signiﬁcant differences were found on comparing
the studied groups versus each other.
Microalbuminuria (20—200g/min) is an eas-
ily measurable parameter assumed to reﬂect
systemic endothelial leakiness, it is used as a
predictor of cardiovascular end organ damage espe-
cially diabetic nephropathy [25]. In diabetes, the
endothelium is stressed by high glycosylation end
products, thus becoming more permeable for albu-
min. Also, disturbed proteoglycan synthesis causes
the glomerular membrane to lose its sensitivity and
integrity [16].
In hypertension, endothelial dysfunction is a
common ﬁnding and high intraglomerular pres-
sure causes increased albumin excretion [25].
Microalbuminuria represents a mirror image of
hypertension and may precede cardiovascular dis-
ease [26]. The increased endothelial leakiness may
facilitate the entrance of lipoproteins and other
proatherogenic mediators [16].
In this work, the mean values of CRP showed
signiﬁcant elevation in diabetic, hypertensive,
obese, and smoker groups compared to controls.
Also in group II (atheroma patients) compared to
group I (patients without atheroma). CRP is con-
sidered of particular importance because of its
reported function as a sensitive and independent
marker of vascular inﬂammation [27]. Inﬂammation
h
c
f
eS.S. El-Gendi et al.
ay be important for accelerated progression of
therosclerosis in patients with hypertension and
iabetes [28]. CRP due to its presence in arte-
ial wall predicts severity of atherosclerosis due
o its ability to bind to damaged membrane, lipid,
ctivate complement, and stimulate tissue factors,
roteins responsible for initiating arterial thrombo-
is [29]. In hypertensive patients, CRP is involved in
omplex pathways leading to endothelial dysfunc-
ion, increased peripheral vascular resistance, and
rterial stiffness [8]. In this study, there was a posi-
ive correlation of CRP with left carotid artery IMT.
orrado et al. [28] reported the same ﬁnding. In
iabetic patients, CRP also can predict coronary
eart disease. Association of inﬂammation, insulin
esistance, and hyperglycemia jointly contribute to
ardiovascular risk [30].
In the present study, mean value of Lp(a) showed
igniﬁcant elevation in smoker group compared to
ontrols, and in other studied groups the mean
alues were high, but statistically insigniﬁcant. In
roup C (FS≥ 20), Lp(a) showed signiﬁcant eleva-
ion compared to group A (FS < 10). Lp(a) has a
igh degree of homology with plasminogen. Athero-
enic hypothesis involves competition between
lasminogen and Lp(a) for ﬁbrin binding sites, suc-
essful competition by Lp(a) will block plasminogen
orming clots, which will not dissolve. So Lp(a)
ttenuates ﬁbrinolysis and promotes coagulation
13]. Lp(a) has been associated with endothe-
ial dysfunction [31]. Lp(a) activate monocytes,
timulates smooth muscle cell migration and pro-
iferation, and could induce inﬂammation [32].
p(a) lacks antioxidant and exhibits high afﬁn-
ty to glucosamine and ﬁbrinogen, which prolongs
he residence time in the arterial subintima, both
haracters of Lp(a) facilitate its oxidative modiﬁ-
ation and promote the formation of foam cells
nd fatty streaks [33]. The complex structural
omology of Lp(a) with LDL and plasminogen sug-
est that Lp(a) might represent the ideal bridge
etween ﬁeld of atherosclerosis and thrombosis in
he pathogenesis of vascular disease [14]. Lp(a)
ould enhance the atherogenic effect of LDL on
oronary atherosclerosis and myocardial infarction
34].
Lp(a) induces chemotactic activity to human
onocytes [35]. Lp(a) accumulates in the suben-
othelial space of the vessels wall and may act as a
otent atherosclerostic agent, independent of Apo
a) size [36].As regards the analysis of the lipid proﬁle,
ypercholesterolemia accelerates atherogenesis by
holesterol accumulation in the arterial intima
ollowing diffusion of lipoprotein across the
ndothelium with fatty streak formation. Over
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ime, these fatty streaks can develop into plaques
hat partially block the blood ﬂow [37].
High triglyceride levels may contribute directly
o atherosclerotic process by triggering endothe-
ial dysfunction, enhanced monocyte adhesion, and
ipid accumulation within arterial wall. Elevated
lasma triglycerides also seem to cause foam cell
ormation [38].
Elevated LDL-c levels in plasma lead to increased
etention of LDL-c in arterial wall, their oxida-
ion, secretion of inﬂammatory mediators, and
hemoattractants [39]. Oxidized LDL-c can change
he elastic properties of arterial wall; it is taken
p by the scavenger receptor on macrophages and
onstitutes the foam cells of atherosclerotic plaque
40]. In this study, there were positive correla-
ions between carotid artery IMT with cholesterol,
riglycerides, and LDL-c and negative correlation
ith HDL-c.
In the present study, plasma tHcy levels revealed
igniﬁcant elevation in diabetic, hypertensive,
bese, and smoker groups compared to controls. No
igniﬁcant differences were found in groups com-
ared versus each other (Framingham score and
theroma groups). Increased plasma tHcy is asso-
iated with microalbuminuria, retinopathy, high
lood pressure, Lp(a), and high level of ﬁbrinogen
41]. Marked elevation of tHcy results in vascular
njury and premature atherothrombosis [42], with
lteration in coagulation process [43]. Autooxida-
ion of tHcy produces reactive oxygen species (ROS)
hich may stimulate lipid peroxidation and forma-
ion of advanced oxidation protein products and
dvanced glycation end products. Interaction of
dvanced glycation end products with their species
eceptor induce formation of ROS. Advanced gly-
ation end products, advanced oxidation protein
roducts, and lipid peroxidation products are impli-
ated in the pathogenesis of degenerative and
nﬂammatory diseases, including atherosclerosis
44].
In obese subjects who are free from atheroscle-
osis or renal function impairment, tHcy levels are
ormal. Also tHcy levels are not related to IMT of
arotid artery during non-atherogenic stage [45].
nﬂammation and hyperhomocysteinemia may be
mportant mechanisms by which smoking promotes
therosclerotic disease [46], in addition to dyslipi-
emia and hypercoagulability [47].
As regards mean values of IMT of carotid and
emoral arteries, they were signiﬁcantly higher
n all studied groups. Also IMT of carotid artery
orrelated with traditional and non-traditional car-
iovascular risk factors. Age, waist circumference,
aist/hip ratio, tHcy, triglycerides, and CRP were
redictors of IMT of carotid arteries, while age,
t
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RP, and triglycerides were independently asso-
iated with atheroma. However, IMT of femoral
rteries revealed no relationship to cardiovascular
isk factors. Several studies have been conducted
o assess determinants of IMT of carotid arter-
es. Lee et al. [48] reported that age, cholesterol,
nd smoking were positively associated with mean
MT, whereas age, cholesterol, and BMI were inde-
endently associated with plaque. The study of
radshaw et al. [49] showed that plaque was pre-
icted by increasing age, history of smoking, and
otal cholesterol/HDL ratio. Also, McDonald et al.
50] found that age, waist circumference, and high
RP were signiﬁcant predictors of carotid IMT.
Mean value of tHcy revealed a positive correla-
ion with IMT of left carotid artery and it was a
trong determinant of IMT. tHcy mediates injury of
lood vessels as it promotes smooth muscle cells
rowth leading to intima—media thickening [51].
ullo et al. [52] reported that plasma tHcy was asso-
iated with coronary artery thickness independent
f CHD risk factors. Also, Adachi et al. [53] found
hat hyperhomocysteinemia is an independent risk
actor for increased carotid artery wall. In con-
rast, Linnebank et al. [54] showed that common
arotid artery IMT was not predicted by tHcy lev-
ls. As regards Lp(a), we did not ﬁnd any relation
etween its level and IMT of carotid and femoral
rteries. In agreement with our results, Srámek et
l. [55] showed a clear association of IMT of carotid
nd femoral arteries with established risk factors,
ut not with Lp(a); in contrast, Linnebank et al. [54]
ound that Lp(a) was a predictor for IMT of common
arotid artery.
In the present study, mean levels of insulin sen-
itivity were signiﬁcantly lower in the atheroma
roup. The study of Sourij et al. [56], showed that
omeostasis model assessment was predictive for
arotid plaque.
onclusions
on-traditional biochemical markers (tHcy, Lp(a),
RP, UAER) were elevated in cardiovascular risk
roups. IMT of carotid and femoral arteries were
levated in all groups. IMT of carotid artery
ositively correlated with traditional risk fac-
ors (systolic and diastolic blood pressure, BMI,
ipogram, and FS) and negatively correlated with
DL. Also, it correlated positively with non-
raditional risk factors (tHcy and CRP). Age, waist
ircumference, waist/hip ratio, tHcy, triglycerides,
nd CRP were predictors of IMT of coronary
rteries, while age, CRP, and triglycerides were pre-
ictors of atheroma. Carotid IMT testing, including
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its precise measurement, may be used as a surro-
gate for atherosclerosis and potential applications
in both primary and secondary coronary heart dis-
ease prevention is recommended.
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